The ULSPIRA Solution™ is a complete offering for nitric oxide therapy

Now there’s an INO therapy that benefits RTs and patients alike

Every second counts when it comes to breathing — especially in the NICU, where your smallest and most vulnerable patients may be struggling to take a breath. As an RT, you know that patients diagnosed with Persistent Pulmonary Hypertension of the Newborn (PPHN) need therapy fast.

That’s why you can’t afford to waste time preparing your equipment, replacing your cylinders or locating the right consumables for your patient’s prescribed therapy. You need everything right at your fingertips and ready to go.

The ULSPIRA Solution is specifically designed with these needs in mind. It includes ULSPIRA, the FDA-cleared nitric oxide gas for inhalation and our easy-to-use nitric oxide (NO) delivery device that helps remove barriers to rapid patient care while it makes your job easier. The solution also includes ULSPIRA Care+™, our customizable program for service and support.

Now you can take advantage of special pricing and terms pre-negotiated by Premier for all your iNO therapy needs. Complete the form for more information.

See the many ways the ULSPIRA Solution brings iNO therapy to the next level

Watch the ULSPIRA Solution video

Spend more time with your patients and less time managing equipment.

Download the ULSPIRA Solution brochure

Removing barriers to patient care allows you to focus more on your patients.

Learn more about the ULSPIRA Solution today

ULSPIRA Indication and Important Safety Information

ULSPIRA (nitric oxide) gas, for inhalation, is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Contraindications

ULSPIRA is contraindicated in neonates dependent on right-to-left shunting of blood.

Warnings and Precautions

• Rebound: Abrupt discontinuation of ULSPIRA may lead to worsening oxygenation and increasing pulmonary artery pressure.
• Methemoglogin: Methemoglobin increases with the dose of ULSPIRA and is dose dependent. Following discontinuation or reduction of nitric oxide, methemoglobin levels can take up to 8 hours or more to return to baseline. If methemoglobin levels do not resolve with decrease in dose or discontinuation of ULSPIRA, additional therapy may be warranted to treat methemoglobinemia.
• Elevated Levels: Monitor for PaO₂, inspired nitrogen dioxide (NO₂), and methemoglobin during ULSPIRA administration.
• Heart Failure: In patients with pre-existing left ventricular dysfunction, ULSPIRA may increase pulmonary capillary wedge pressure, leading to pulmonary edema.
• Nitrogen dioxide may cause airway inflammation and damage to lung tissues.

Adverse Reactions

The most common adverse reaction of ULSPIRA is hypotension.

Drug Interactions

Nitric Oxide donor compounds may increase the risk of developing methemoglobinemia.

Use With Delivery System

ULSPIRA must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System operated by trained personnel. Only validated ventilator systems should be used in conjunction with ULSPIRA.

Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full ULSPIRA prescribing information for additional ULSPIRA safety and risk information.